Q BioMed Inc.’s Chemotherapeutic Uttroside B Shows Promising Results in Initial Pre-Clinical Testing
Q BioMed Inc. (OTCQB:QBIO)
ATLANTA, GA, UNITED STATES, August 25, 2021 /EINPresswire.com/ — Q BioMed Inc. is an acceleration and commercial stage company focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed just announced that their asset Uttroside B – is expected to receive a patent in Korea, adding to the already issued patents in Canada and Japan. In addition, recent results from pre-clinical pharmacokinetic testing have been very encouraging and the data supports advancing the program. Uttroside B shows tremendous value in the Liver Cancer Market. Uttroside B has also received Orphan Drug designation from the FDA.
Cancer.com reported in this year alone, an estimated 42,230 adults in the United States will be diagnosed with primary liver cancer. It is also estimated that 30,230 deaths from this disease will occur this year. The 5-year survival rate is 20%, compared to just 3% 40 years ago. For the 44% of people who are diagnosed with liver cancer at an early stage, the 5-year survival rate is 34%. There is significant demand for better therapeutic alternatives in the space.
Q BioMed announced in January that it has received Orphan Drug Status from the FDA. Q BioMed Inc. is prosecuting patents in multiple jurisdictions and has received patents from Canada and Japan and has now received notice of an allowable patent in South Korea. The Patent is titled “Uttroside-B and Derivatives Thereof as Therapeutics for Hepatocellular Carcinoma (HCC)”. Q BioMed has the exclusive rights to the technology through an agreement with the Rajiv Gandhi Centre for Biotechnology, an Autonomous Institute under the Department of Biotechnology, Government of India, and the Oklahoma Medical Research Foundation.
The global liver cancer drug market size was valued at US$824 Million in 2020 and is anticipated to grow at a CAGR of 29.4% during forecast period 2021 to 2030. In early pre-clinical investigation Q BioMed’s Uttroside-B showed ten times the cytotoxicity against HCC, which is the toxicity caused due to the action of the chemotherapeutic agent on living cancer cells, as compared to the current standard of care drug at the time. Currently, there are only two approved first-line mono therapies and a combination first-line therapy for HCC. Challenges with current treatments include patients becoming resistant to the specific drugs, adverse side effects, and high costs.
About Landon Capital
Landon Capital was founded in 2017 and has assisted hundreds of emerging growth companies increase their shareholders and build relationships on Wall Street. We design customized programs to increase the market’s interest in your company. For more information, please visit www.landoncapital.net
Safe Harbor Statement
This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. Landon Capital received no direct compensation related to this release, although Landon Capital does hold a position in the company covered above. This release contains certain forward-looking statements based on current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Actual results may differ materially from those stated or implied in such forward-looking statements. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” and “would” or similar words. We assume no obligation to update the information included in this press release, whether because of new information, future events or otherwise.
email us here